Spots Global Cancer Trial Database for adavosertib

Every month we try and update this database with for adavosertib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)	NCT04439227	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult...	Adavosertib	18 Years -	National Cancer Institute (NCI)
Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	NCT02272790	Ovarian, Fallop...	Adavosertib Paclitaxel Carboplatin Gemcitabine PLD	18 Years - 130 Years	AstraZeneca
Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2	NCT03284385	Clear Cell Rena... Locally Advance... Locally Advance... Metastatic Mali... Metastatic Rena... Stage III Renal... Stage IV Renal ...	Adavosertib	18 Years -	National Cancer Institute (NCI)
Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia	NCT02381548	Acute Myeloid L... Blast Phase Chr... Myelodysplastic... Previously Trea... Recurrent Adult... Recurrent Chron... Refractory Acut... Refractory Chro... Secondary Acute... Therapy-Related... Untreated Adult...	Adavosertib Belinostat Laboratory Biom... Pharmacological...	18 Years -	National Cancer Institute (NCI)
A Dose Escalation Study of Adavosertib (MK-1775) in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001)	NCT00648648	Solid Tumors	adavosertib gemcitabine cisplatin carboplatin	18 Years -	Merck Sharp & Dohme LLC
A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours	NCT04949425	Advanced Solid ...	Adavosertib	18 Years - 130 Years	AstraZeneca
MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations	NCT01827384	Advanced Malign...	Adavosertib Carboplatin Everolimus Temozolomide Trametinib Veliparib	18 Years -	National Cancer Institute (NCI)
AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification	NCT03253679	Advanced Malign... Refractory Mali...	Adavosertib	18 Years -	National Cancer Institute (NCI)
Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	NCT02101775	Ovarian Brenner... Ovarian Carcino... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Serous ... Ovarian Undiffe... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Adavosertib Gemcitabine Hyd... Laboratory Biom... Pharmacological... Placebo Adminis... Questionnaire A...	18 Years -	National Cancer Institute (NCI)
A Study of Adavosertib (MK-1775) in Combination With Topotecan/Cisplatin in Participants With Cervical Cancer (MK-1775-008)	NCT01076400	Cervical Cancer	adavosertib Topotecan Cisplatin Placebo to adav...	18 Years -	Merck Sharp & Dohme LLC
A Study of Adavosertib as Treatment for Uterine Serous Carcinoma	NCT04590248	Uterine Serous ...	Adavosertib	18 Years - 130 Years	AstraZeneca
Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	NCT02659241	Advanced Fallop... Advanced Ovaria... Advanced Primar... Carcinomatosis Fallopian Tube ... Ovarian High Gr... Primary Periton... Stage III Fallo... Stage III Ovari... Stage III Prima... Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar...	Adavosertib Laboratory Biom...	18 Years -	M.D. Anderson Cancer Center
A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib	NCT04959266	Advanced Solid ...	Adavosertib Itraconazole Rifampicin Omeprazole	18 Years - 130 Years	AstraZeneca
Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)	NCT04439227	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult...	Adavosertib	18 Years -	National Cancer Institute (NCI)
A Dose Escalation Study of Adavosertib (MK-1775) in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001)	NCT00648648	Solid Tumors	adavosertib gemcitabine cisplatin carboplatin	18 Years -	Merck Sharp & Dohme LLC
Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	NCT02272790	Ovarian, Fallop...	Adavosertib Paclitaxel Carboplatin Gemcitabine PLD	18 Years - 130 Years	AstraZeneca
Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2	NCT03284385	Clear Cell Rena... Locally Advance... Locally Advance... Metastatic Mali... Metastatic Rena... Stage III Renal... Stage IV Renal ...	Adavosertib	18 Years -	National Cancer Institute (NCI)
Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	NCT03579316	Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Adavosertib Olaparib Ceralasertib	18 Years -	M.D. Anderson Cancer Center
Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers	NCT03345784	Cervical Carcin... Endometrioid Ad... Malignant Femal... Recurrent Cervi... Stage I Uterine... Stage I Vaginal... Stage IA Uterin... Stage IB Cervic... Stage IB Uterin... Stage IB2 Cervi... Stage II Cervic... Stage II Uterin... Stage II Vagina... Stage IIA Cervi... Stage IIB Cervi... Stage III Cervi... Stage III Uteri... Stage III Vagin... Stage IIIA Cerv... Stage IIIA Uter... Stage IIIB Cerv... Stage IIIB Uter... Stage IIIC Uter... Vaginal Carcino...	Adavosertib Cisplatin External Beam R...	18 Years -	National Cancer Institute (NCI)
Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma	NCT01849146	Glioblastoma Recurrent Gliob...	Adavosertib Radiation Thera... Temozolomide	18 Years -	National Cancer Institute (NCI)
Adavosertib and Gemcitabine in Advanced Pancreatic	NCT05212025	Pancreatic Canc...	Adavosertib Gemcitabine	18 Years -	Dana-Farber Cancer Institute
A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours	NCT04949425	Advanced Solid ...	Adavosertib	18 Years - 130 Years	AstraZeneca
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas	NCT01922076	Anaplastic Astr... Anaplastic Olig... Diffuse Intrins... Diffuse Midline... Glioblastoma Gliosarcoma	Adavosertib Laboratory Biom... Pharmacological... Radiation Thera...	37 Months - 21 Years	National Cancer Institute (NCI)
Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours	NCT02617277	Advanced Solid ...	AZD1775 MEDI4736	18 Years - 130 Years	AstraZeneca
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	NCT02465060	Advanced Lympho... Advanced Malign... Bladder Carcino... Breast Carcinom... Cervical Carcin... Colon Carcinoma Colorectal Carc... Endometrial Car... Esophageal Carc... Gastric Carcino... Glioma Head and Neck C... Hematopoietic a... Kidney Carcinom... Liver Carcinoma Lung Carcinoma Lymphoma Malignant Uteri... Melanoma Multiple Myelom... Ovarian Carcino... Pancreatic Carc... Prostate Carcin... Rectal Carcinom... Recurrent Bladd... Recurrent Breas... Recurrent Cervi... Recurrent Colon... Recurrent Color... Recurrent Esoph... Recurrent Gastr... Recurrent Gliom... Recurrent Head ... Recurrent Liver... Recurrent Lung ... Recurrent Lymph... Recurrent Malig... Recurrent Melan... Recurrent Multi... Recurrent Ovari... Recurrent Pancr... Recurrent Prost... Recurrent Recta... Recurrent Skin ... Recurrent Thyro... Recurrent Uteri... Refractory Lymp... Refractory Mali... Refractory Mult... Skin Carcinoma Thyroid Gland C... Uterine Corpus ...	Adavosertib Afatinib Afatinib Dimale... Binimetinib Biopsy Biospecimen Col... Capivasertib Computed Tomogr... Copanlisib Copanlisib Hydr... Crizotinib Cytology Specim... Dabrafenib Dabrafenib Mesy... Dasatinib Defactinib Defactinib Hydr... Echocardiograph... Erdafitinib Fexagratinib Ipatasertib Laboratory Biom... Larotrectinib Larotrectinib S... Magnetic Resona... Multigated Acqu... Nivolumab Osimertinib Palbociclib Pertuzumab PI3K-beta Inhib... Radiologic Exam... Radionuclide Im... Relatlimab Sapanisertib Sunitinib Malat... Taselisib Trametinib Trastuzumab Trastuzumab Emt... Ulixertinib Vismodegib	18 Years -	National Cancer Institute (NCI)
A Study of Adavosertib (MK-1775) in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)	NCT01357161	Ovarian Cancer	adavosertib Placebo paclitaxel carboplatin	18 Years -	Merck Sharp & Dohme LLC
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors	NCT02095132	Central Nervous... Central Nervous... Central Nervous... Embryonal Tumor... Pineoblastoma Primary Central... Recurrent Child... Recurrent Malig... Recurrent Medul... Recurrent Neuro... Recurrent Rhabd... Refractory Mali... Refractory Medu... Refractory Neur... Refractory Rhab...	Adavosertib Irinotecan Hydr...	1 Year - 21 Years	National Cancer Institute (NCI)
A Study of Adavosertib (MK-1775) in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)	NCT01357161	Ovarian Cancer	adavosertib Placebo paclitaxel carboplatin	18 Years -	Merck Sharp & Dohme LLC
Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study	NCT04197713	Advanced Malign... Metastatic Mali... Refractory Mali... Unresectable Ma...	Adavosertib Olaparib	18 Years -	National Cancer Institute (NCI)
Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers	NCT04460937	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Distal Esophagu... Gastric Cardia ... Metastatic Esop... Metastatic Esop... Metastatic Gast... Metastatic Mali... Metastatic Mali... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Unresectable Es... Unresectable Es... Unresectable Es... Unresectable Ga...	Adavosertib Radiation Thera...	18 Years -	National Cancer Institute (NCI)
Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	NCT02101775	Ovarian Brenner... Ovarian Carcino... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Serous ... Ovarian Undiffe... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Adavosertib Gemcitabine Hyd... Laboratory Biom... Pharmacological... Placebo Adminis... Questionnaire A...	18 Years -	National Cancer Institute (NCI)
Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	NCT03579316	Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Adavosertib Olaparib Ceralasertib	18 Years -	M.D. Anderson Cancer Center
A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours	NCT04949425	Advanced Solid ...	Adavosertib	18 Years - 130 Years	AstraZeneca
AZD1775 for Advanced Solid Tumors	NCT01748825	Solid Tumors	MK-1775 (AZD177...	18 Years - 120 Years	National Institutes of Health Clinical Center (CC)

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world:

Spots Global Cancer Trial Database for adavosertib

Every month we try and update this database with for adavosertib cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for adavosertib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.